Delayed motor response correlates with striatal degeneration in Parkinson's disease

Acta Neurologica Scandinavica

Volumn 100, Issue 4, 1999, Pages 227-230

  Müller, Thomas ^a   Eising, E ^b   Kuhn, W ^a   Buttner T ^a   Coenen, H H ^b,c   Przuntek, H ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

Movement time; Reaction time; Striatal degeneration

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPAMINE; IODINE 123;

ADULT; AGE; AGED; ARTICLE; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; REACTION TIME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0032840159     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1999.tb00385.x     Document Type: Article

References (18)

1. 1. Jahanshahi M, Brown RG, Marsden CD. A comparative study of simple and choice reaction time in Parkinson's, Huntington's and cerebellar disease. J Neurol Neurosurg Psychiatry 1993;56:1169-77.
2. 2. Jahanshahi M, Brown RG, Marsden CD. The effect of withdrawal of dopaminergic medication on simple and choice reaction time and the use of advance information in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55:1168-76.
3. 3. Pullman SL, Watts RL, Juncos JL, Sanes JN. Movement amplitude choice reaction time performance in Parkinson's disease may be independent of dopaminergic status. J Neurol Neurosurg Psychiatry 1990;53:279-83.
4. 4. Pullman SL, Watts RL, Juncos JL, Chase TN, Sanes JN. Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease. Neurology 1988; 38:249-54.
5. 5. Stern Y, Mayeux R, Rosen J. Contribution of perceptual motor dysfunction to construction and tracing disturbances in Parkinson's disease. J Neurol Neurosurg Psychiatry 1984;47:983-9.
6. 6. Zappia M, Montesanti R, Colao R, Quattrone A. Usefulness of movement time in the assessment of Parkinson's disease. J Neurol 1994;241:543-50.
7. 7. Lalonde R, Botez-Marquard T. The neurological basis of movement initiation. Rev Neurosci 1997;8:35-54.
8. 8. Weed MR, Gold LH. The effects of dopaminergic agents on reaction time in rhesus monkeys. Psychopharmacology 1998;137:33-42.
9. 9. Yamaguchi S, Kobayashi S. Contributions of the dopaminergic system to voluntary and automatic orienting of visuospatial attention. J Neurosci 1998;18:1869-78.
10. 123I]-β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-98.
11. 11. Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996;60:634-7.
12. 12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr 1992;55:181-4.
13. 123,124I]-β-CIT, plasma analysis and pharmacokinetic studies with SPECT and PET. Nucl Med Biol 1995;8:977-84.
14. 14. Harrison J, Henderson L, Kennard C. Abnormal refractoriness in patients with Parkinson's disease after brief withdrawal of levodopa treatment. J Neurol Neurosurg Psychiatry 1995;59:499-506.
15. 15. Baunez C, Nieoullon A, Amalric M. In a rat model of parkinsonism, lesions of the subthalamic nucleus reverse increases of reaction time but induce a dramatic premature responding deficit. J Neurosci 1995;15:6531-41.
16. 16. Ward NM, Brown VJ. Covert orienting of attention in the rat and the role of striatal dopamine. J Neurosci 1996; 16:3082-8.
17. 17. Braak H, Braak E, Yilmazer D, de Vos Rai, Jansen ENH. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl 1995;46:15-32.
18. 18. Braak H, Braak E, Yilmazer D, de Vos Rai, Jansen ENH, Bohl J. New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease. J Neural Transm Suppl 1996;48:1-6.